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1. Introduction 
Protein glycosylation is a ubiquitous post-translational 
modification, thought to occur on more than 50% of human 
proteins.1 In eukaryotic organisms, glycoproteins mediate diverse 
functions, including cell-cell communication, signal transduction 
and pathogenesis.2 There exist two major classes of protein 
glycosylation, known as N- and O-linked glycosylation, which 
are classified according to the type of linkage to the amino acid 
side chain within the polypeptide backbone. O-linked glycans 
encompass a diverse range of structures which are attached 
through the hydroxyl group of serine, threonine, hydroxyproline, 
hydroxylysine or tyrosine.3,4 In contrast, N-linked glycans exhibit 
limited diversity and are generally characterized by the presence 
of a common Man3GlcNAc2 pentasaccharide core, with the 
reducing terminal N-acetylglucosamine β-linked to the nitrogen 
atom of the asparagine amide side chain located within an Asn-
Xaa-Ser/Thr consensus sequence.4,5 Other forms of Asn-N-linked 
protein glycosylation are known but are exceedingly rare.6-9 
In recent years, novel examples of N-glycosylation have been 
identified in plants,10-12 bacteria13-15 and humans,16,17 whereby the 
sugar is linked to the ω-nitrogen of the guanidine moiety within 
the arginine (Arg) side chain. For instance, N-rhamnosyl-Arg was 
recently discovered as a modification in the protein elongation 
factor P expressed by pathogenic bacteria, such as Pseudomonas 
aeruginosa, Shewanella oneidensis and Neisseria meningitidis.13-
15 The presence of this modification was shown to be critical for 
each protein to prevent ribosome stalling during the translation of 
proline-proline motifs. The anomeric centre of the rhamnose 
motif was recently shown to have α-configuration through NMR 
analysis of the native EF-P glycoprotein18 and through NMR and 
mass spectroscopic comparison of synthetic α- and β-linked 
glycopeptides with native and chemoenzymatically synthesized 
EF-P fragments.19  
Figure 1. Complementary approaches for the preparation of native Arg-Nω-
glycosylated peptides. (a) solid phase guanidinylation approach, (b) cassette 
strategy with preformed glycosylated Arg building blocks. 
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A further modification of Arg, β-GlcNAcylation has also been 
discovered in various human proteins bearing a death domain, 
including TRADD, FADD, TNFR1 and the kinase RIPK1.16,17,20 
In this case the post-translational modification was shown to be 
introduced by the glycosyltransferase activity of NIeB, a type III 
secretion system effector protein produced by attaching/effacing 
enteropathogenic strains of Escherichia coli. Interestingly, it was 
shown that GlcNAcylation of the Arg residue could functionally 
block the assembly of death-inducing signaling complex, 
effectively preventing E.coli-infected cells from undergoing 
apoptosis and necroptosis.16,17 The importance of this protein 
modification elicited by E. coli to avoid regulatory clearance  
within mammalian cells suggests that this process might serve as 
a future adjuvant antimicrobial target.21  
Recently Hu and co-workers reported synthetic routes to β-
GlcNAcylated and α-rhamnosylated Arg-containing 
glycopeptides employing Ag-promoted on-resin guanidinylation 
of fully elongated and resin-bound peptides with an unprotected 
ornithine residue (Figure 1a).18,22 These methods enabled the 
generation of peptides to which antibodies selective to the 
glycosylated Arg modifications could be raised.18,22 Although the 
on-resin glycosylation strategy provided a direct and divergent 
route to glycosylated Arg glycopeptides, it is possible that the 
efficiency of this strategy could vary depending on the size and 
sequence of the peptide substrate. On-resin glycosylation of 
peptides requires the site of functionalisation to be solvent-
accessible, which becomes less likely as the peptide length and 
number of β-sheet inducing amino acids increases. As a 
complementary approach, we recently prepared α- and β-linked 
rhamnosylated peptides through the so called ‘cassette’ strategy 
via the synthesis of Nα-Fmoc and side chain-protected α- and β-
linked rhamnosyl Arg building blocks and subsequent 
incorporation into target glycopeptides through Fmoc-SPPS 
(Figure 1b).19 Our rationale for this approach was that the 
introduction of a suitable glycosylamino acid ‘cassette’ could 
serve as an alternative method for the introduction of the 
glycosylarginine moiety and would streamline access to 
glycopeptide libraries without the need to perform ornithine 
deprotection and guanidinylation on each resin-bound substrate. 
The successful implementation of this cassette strategy for 
introduction of the rhamnosylated Arg moiety prompted us to 
extend the methodology for the synthesis of biologically-relevant 
GlcNAcylated Arg glycopeptides that we report herein. 
The synthesis of an effective glycosylamino acid building 
block for introduction of the Nω-GlcNAc-β-Arg moiety is 
dependent on appropriate protection of the Arg side chain, which 
would otherwise intramolecularly attack the α-carboxylic active 
ester during glycosylamino acid coupling, leading to an 
unproductive lactam derivative. Previous attempts by us 
(unpublished results), and the Hu group,22 to implement the 
‘cassette’ strategy have revealed that GlcNAcylated and 
rhamnosylated Arg building blocks bearing mono-Nω’-Boc and 
mono-Nω’-trifluoroacetyl23 protecting groups couple very slowly 
to resin-bound peptides and are still prone to intramolecular 
lactamization during coupling. To address this limitation, and 
improve the viability of the glycosylamino acid building block 
approach for the synthesis of Arg-N-linked glycopeptides, we 
reported the synthesis of Arg-Nω-rhamnosylated glycosylamino 
acid building blocks bearing the electron withdrawing Nω’-
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) side 
chain protecting group, which is commonly used for the 
protection of the standard guanidine side chain of Arg during 
Fmoc-SPPS.24 Arg-Nω-rhamnosylated glycosylamino acids with 
the side chain Pbf protection were demonstrated to couple 
efficiently to resin-bound peptides and did not undergo 
unproductive lactamization. Herein, we report the efficient 
synthesis of an analogous glycosylamino acid bulding block 1, 
for the introduction of the GlcNAc-β-Arg modification, and 
demonstrate its effective use for the synthesis of biologically 
relevant death domain-derived glycopeptides through Fmoc-
SPPS. 
2. Results and Discussion 
 Synthesis of GlcNAcylated Arg building block 1 began from 
glycosyl β-isothiocyanate 2, which was prepared in two steps 
according to established methods (Scheme 1).22 The 
isothiocyanate was subsequently treated with deprotonated Pbf-
NH2, which could be generated by pre-mixing Pbf-NH2 with 
KOtBu.25 The resulting Pbf-thiourea 3 was not isolated, but 
immediately alkylated with EtI to afford the ethyl isothiourea 4 in 
82% yield over the two steps. The ethyl isothiourea then 
underwent a Hg-promoted guanidinylation with Fmoc-Orn-OAll 
to form the allyl ester 5 in good yield. From here allyl 
deprotection, catalyzed by Pd(PPh3)4, afforded the desired 
building block 1 in 63% yield (39% overall yield over the 4 steps 
from 2). 
As the 1H NMR spectrum of glycosylamino acids 1 and 5 
exhibited significant broadening of the pyranose signals on 
account of a tautomeric or rotameric effect, the Pbf group of 1 
was removed for characterisation purposes to yield free 
guanidine 6, which could be more clearly interrogated by NMR 
spectroscopy. The extraction of a large anomeric coupling 
constant (J1,2 = 9 Hz) confirmed the β-stereochemistry of the 
anomeric linkage.  
Having successfully synthesized and characterized the desired 
glycosylamino acid building block 1, we directed focus towards 
the synthesis of two target GlcNAcylated Arg glycopeptides 
through Fmoc SPPS (Scheme 2). We chose to synthesize 
glycopeptides 7 and 8 representing fragments of both human 
TRADD(232-239) and mouse FADD(115-125)  death domains, 
each encompassing a central GlcNAcylated Arg residue. After 
loading the two C-terminal amino acids separately onto 
Chemmatrix® Trtyl-OH resin,26 each resin-bound amino acid 
was elongated towards the glycosylation site using DIC/Oxyma 
coupling conditions to afford resin-bound peptides 9 and 10. 
Each of the resin-bound peptides were then treated with a 
mixture of GlcNAcylated Arg cassette 1 (2.2 equiv.), 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
Scheme 1. Synthesis of GlcNAcylated Arg glycosylamino acid ‘cassette’ 1 
 
b]pyridinium 3-oxide hexafluorophosphate (HATU, 2.0 equiv.), 
1-Hydroxy-7-azabenzotriazole (HOAt, 3.0 equiv.) and sym-
collidine (2.4 equiv.).27 These conditions facilitated complete 
incorporation of the glycosylamino acid as judged by analytical 
test cleave with TFA:i-Pr3SiH:H2O (18:1:1 v/v/v) followed by 
UPLC-MS analysis. The resulting two resin-bound glycopeptides 
11 and 12 were further elongated under DIC/oxyma coupling 
conditions to afford the target resin-bound glycopeptides.  From 
here, the resin-bound glycopeptides were treated with an acidic 
cocktail (TFA:iPr3SiH,H2O; 18:1:1 v/v/v) to deprotect the peptide 
side chains and liberate the peptide from the resin. Finally, 
Zemplén deacetylation28 was used to deprotect the O-acetate 
protecting groups on the GlcNAc moiety, to afford the desired 
TRADD(232-239) and FADD(115-125) glycopeptides 7 and 8 in 
26% and 33% yield, respectively after reverse-phase HPLC 
purification (yields based on the Fmoc-loading of the C-terminal 
amino acid residue immobilized to resin). 
A curious feature of α-N-rhamnosylated Arg glycopeptides is 
the tendency for anomerization in organic solvent under basic 
conditions, such as during deacetylation of the carbohydrate 
protecting groups with NaOMe/MeOH and hydrazine/DMF.19 To 
ensure that this did not occur during the synthesis of N-
GlcNAcylated TRADD(232-239) and FADD(115-125) peptides, 
both glycopeptides were characterized by a combination of 1H 
NMR spectroscopy, and 2D COSY and HSQC. In both cases, the 
magnitude of the anomeric coupling constant (J1,2 = 9.7 Hz) 
confirmed that the β-stereochemistry was retained during SPPS 
and deacetylation (see Supporting Information for NMR data). 
The results are consistent with the observation that the synthetic 
β-N-rhamnosylated counterpart, which also contains an 
equatorial anomeric linkage, was resistant to base catalysed 
anomerization.19 These results support the notion that equatorial 
Arg-N-glycosidic linkages are more thermodynamically stable 
than their axial counterparts.  
3. Conclusions 
 In summary, we have developed a new method for the 
synthesis of biologically-relevant glycopeptides containing the 
recently discovered GlcNAc-β-N-Arg linkage. Key to this 
methodology was the synthesis of a suitably protected 
GlcNAcylated Arg ‘cassette’ bearing side chain Pbf protection 
that could be synthesised in excellent overall yield in a short 
synthetic sequence. The building block was successfully 
incorporated into death domain fragments of TRADD(232-239) 
and FADD(115-125)  peptides bearing the β-GlcNAcylated 
modification of Arg. The current methodology should find 
application in the study of proteins bearing this modification 
within death domains, and for the synthesis and interrogation of 
newly discovered proteins that contain the unusual GlcNAc-β-
Arg post-translational modification. 
Scheme 2. Synthesis of GlcNAcylated Arg-containing TRADD(232-239) and FADD(115-125) glycopeptides. 
4. Experimental 
4.1 General experimental procedures 
 All reactions were carried out under an argon atmosphere. 
Commercially available chemicals were obtained from Sigma-
Aldrich, Merck, AK Scientifc Inc. or GL Biochem. All 
commercial materials were used as received without further 
purification unless otherwise noted. Flash chromatography was 
performed on silica gel (0.040 – 0.060 mm) manufactured by 
Grace. Solid-phase peptide synthesis (SPPS) was carried out in 
polypropylene syringes equipped with Teflon filters, purchased 
from Torviq. Dichloromethane was purchased from Merck. 
Peptide synthesis grade DMF was purchased from Labscan. 
Chemmatrix® Trtyl-OH resin was purchased from PCAS 
Biomatrix Inc. 
All NMR spectra were recorded at 300 K using a Bruker 
Avance DRX400 or DRX500 spectrometer. Chemical shifts are 
reported in parts per million (ppm) and are referenced to solvent 
residue signals. Proton assignments were made with the 
assistance of COSY spectra. For 2D HSQC spectra contours, 
black represents positive cross peaks and red represents negative 
cross peaks. 
Infrared (IR) absorption spectra were recorded on a Bruker 
ALPHA Spectrometer with Attenuated Total Reflection (ATR) 
capability using OPUS 6.5 software. Compounds were deposited 
as films on the ATR plate via solid compression. Optical 
rotations were recorded at ambient temperature (293K) on a 
Perkin–Elmer 341 polarimeter at 589 nm (sodium D line) with a 
cell path length of 1 dm, and the concentrations are reported in 
g/100 mL. 
All HPLC separations were performed using a buffer 
consisting of 0.1% TFA in H2O (solvent A) and 0.1% TFA in 
MeCN (solvent B). Preparative reverse-phase HPLC was 
performed on a Waters 2535 quaternary gradient module, 
equipped with a Waters 2489 UV detector operating at 214 nm 
using Waters Empower 3 software. Separations of building block 
1 and small molecule intermediates were performed on a Waters 
XBridge OBD C18 50 mm x 150 mm preparative column at a 
flow rate of 38 mL/min. Separations of glycopeptides 7 and 8 
were performed on a Waters XBridge OBD C18 30 mm x 150 
mm preparative column at a flow rate of 7 mL/min. Analytical 
HPLC was performed on a Waters e2695 separations module 
equipped with a Waters 2489 UV/Vis detector operating at 214 
nm. The separations were achieved on a Waters Atlantis T3 
column using a gradient of 0% B for 1 min, followed by 0% B to 
30% B over 15 min with a flow rate of 0.4 mL/min.  
Reaction monitoring by UPLC-MS was performed on a 
Shimadzu NexeraX2 UPLC equipped with a SPD-M30A diode 
array detector and a LCMS-2020 low resolution ESI mass 
spectrometer operating in positive ion mode. Samples were 
analyzed with an Acquity UPLC® BEH C18 1.7 µm, 2.1 x 50 
mm column using eluents of MeCN (0.1% formic acid) and H2O 
(0.1% formic acid) and gradients as specified. High Resolution 
ESI+ mass spectra were obtained on a Bruker Apex Qe 7T 
Fourier Transform Ion cyclotron resonance mass spectrometer 
equipped with a ESI/MALDI (Nd:YAG) dual source. Low 
Resolution MALDI-TOF mass spectra was recorded on a Bruker 
AutoflexTM Speed MALDI-TOF mass spectrometer operating in 
reflectron mode. 
4.2 Synthesis of glycosylamino acid building block 
Glycosyl isothiocyanate 2 was synthesized according to the 
method described by Pan et al.22  
4.2.1: 1-(2,2,4,6,7-Pentamethyldihydrobenzofuran-5-
sulfonyl)-3-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-
glucopyranosyl)-2-ethylisothiourea (4) 
A solution of Pbf-NH2 (1.4 g, 5.2 mmol) and KOtBu (0.60 g, 
5.0 mmol) in anhydrous THF (20 mL) was stirred under an argon 
atmosphere for 1 h. A solution of GlcNAc isothiocyanate 2 (2.0 
g, 5.2 mmol) in THF (10 mL) was added dropwise to the reaction 
mixture. After 3 h, the solution was neutralized with Amberlite® 
IR-120 ion exchange resin. After filtration, the filtrate was 
concentrated under reduced pressure. The crude mixture was 
dissolved in anhydrous MeCN (20 mL) under an argon 
atmosphere. Anhydrous K2CO3 (3.4 g, 25 mmol) was added into 
the reaction followed by EtI (800 μL, 10 mmol). The mixture was 
stirred at 25 °C for 16 h. After the reaction was complete 
(monitored by UPLC-MS), the mixture was concentrated and 
purified by HPLC (20% to 80% B over 20 min) yielding the 
desired isothiourea 4 (2.9 g, 4.2 mmol, 82%) as a white foam. 
[α]D 2.0 (c 0.4, methanol). IR: 3282 (N-H), 1743 (C=O), 1370 
(S=O), 1156 (S=O) cm-1. 1H NMR (400 MHz, d6-acetone): δ 
7.40 (br, NH), 5.37 (tapt, 1H, J2,3 = J3,4 = 10.0 Hz, H-3), 5.27 (d, 
1H, J1,2 = 9.8 Hz, H-1), 5.02 (tapt, 1H, J3,4 = J4,5 = 9.7 Hz, H-4), 
4.26 (dd, 1H, J5,6a = 5.0 Hz, J6a,6b = 12.3 Hz, H-6a), 4.15 (tapt, 1H, 
J1,2 = J2,3 = 10.0 Hz, H-2), 4.07 (dd, 1H, J5,6b = 2.3 Hz, J6a,6b = 
12.3 Hz, H-6b), 3.92 (ddd, 1H, J4,5 = 10.0 Hz, J5,6a = 5.2 Hz, J5,6b 
= 2.3 Hz, H-5), 3.04 (s, 2H, Ar-CH2), 2.95 (q, 2H, J = 7.5 Hz, S-
CH2-CH3), 2.57 (s, 3H, Ar-CH3), 2.51 (s, 3H, Ar-CH3), 2.08 (s, 
3H, Ar-CH3), 2.02 (s, 3H, Ac), 2.01 (s, 3H, Ac), 1.99 (s, 3H, Ac), 
1.91 (s, 3H, Ac), 1.47 (s, 6H, C-(CH3)2), 1.20 (t, 3H, J = 7.3 Hz, 
S-CH2-CH3) ppm. 13C NMR (100 MHz, d6-acetone): δ 169.8 , 
169.2, 159.0, 138.7, 133.0, 124.9, 117.0, 86.6, 81.9, 73.1, 72.4, 
68.8, 61.8, 52.8, 42.5, 27.8, 25.4, 22.0, 19.8, 19.7, 19.7, 18.5, 
17.3, 13.5, 11.5 ppm. HRMS: (+ESI) Calcd. for C30H44N3O11S2 
[M + H]+ m/z, 686.2414; found: 686.2412. 
4.2.2: Nα-[(9H-Fluoren-9-yl)-methoxycarbonyl]-Nω-
(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-Nω’-(2-
acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-L-
arginine allyl ester (5) 
To a solution of isothiourea 4 (0.37 g, 0.54 mmol), Fmoc-Orn-
OAll (0.39 g, 1.0 mmol) and NEt3 (280 μL, 2.0 mmol) in 
chloroform (10 mL) was added HgCl2 (0.16 g, 0.6 mmol). The 
mixture was stirred at 25 °C for 2 h. After completion (monitored 
by TLC), the mixture was filtered through a pad of Celite®. The 
filtrate was concentrated and purified by HPLC to yield the 
desired GlcNAcylated Arg allyl ester 5 (410 mg, 0.39 mmol, 
72%). [α]D -11 (c 0.98, methanol). IR: 3315 (N-H), 1741 (C=O), 
1367(S=O), 1156 (S=O) cm-1. 1H NMR (500 MHz, d6-acetone): 
δ 7.85 (d, 2H, J = 7.5 Hz, Ar-H), 7.70 (ddapt, 2H, J = 7.3 Hz, J = 
2.5 Hz, Ar-H), 7.40 (tapt, 2H, J = 7.4 Hz, Ar-H), 7.31 (tapt, 2H, J = 
7.4 Hz, Ar-H), 6.97 (br, 1H, Fmoc-NH), 6.00-5.80 (m, 1H, O-
CH2-CH=CH2), 5.34 (dq, 1H, J1 = 17.3 Hz, J2 = 1.4 Hz, O-CH2-
CH=CH2), 5.29-5.24 (br, 2H, 2 x GlcNAc-H), 5.18 (dq, 1H, J1 = 
10.5 Hz, J2 = 1.4 Hz, O-CH2-CH=CH2), 5.00 (t, 1H, J = 9.7 Hz, 
GlcNAc-H), 4.60 (d, 2H, J = 4.5 Hz, O-CH2-CH=CH2), 4.50-
4.30 (m, 2H, J = 7.0 Hz, FmocCH-CH2-O-CO), 4.30-4.10 (m, 
3H, FmocCH-CH2-O-CO, Arg-Hα, GlcNAc-H6a), 4.10-3.97 (br, 
3H, 2 x GlcNAc-H, GlcNAc-H6b), 3.40-3.10 (m, 2H, Arg-Hδ), 
2.97 (s, 2H, Ar-CH2), 2.57 (s, 3H, Ar-CH3), 2.49 (s, 3H, Ar-
CH3), 2.05 (s, 3H, Ar-CH3), 1.96 (sapt, 6H, 2 x Ac), 1.95 (s, 3H, 
Ac), 1.88 (sapt, 4H, Ac, Arg-Hβa), 1.85-1.75 (m, 1H, Arg-Hβb), 
1.75-1.60 (m, 2H, Arg-Hγ), 1.42 (s, 6H, C-(CH3)2) ppm. 13C 
NMR (100 MHz, d6-acetone): 171.9, 170.0, 170.0, 169.3, 158.4, 
156.4, 156.4, 154.5, 154.5, 144.3, 144.2, 141.4, 138.2, 134.3, 
132.6, 132.2, 127.8, 127.2, 127.2, 125.4, 125.4, 124.7, 120.1, 
117.6, 116.8, 86.3, 81.4, 72.9, 72.7, 68.9, 66.4, 65.3, 62.0, 54.1, 
54.1, 53.1, 47.3, 42.8, 40.8, 28.0, 25.8, 22.2, 22.2, 19.9, 19.9, 
19.9, 18.8, 17.5, 11.8 ppm. HRMS: (+ESI) Calcd. for 
C51H64N5O15S  [M + H]+ m/z, 1018.4114, found: 1018.4118. 
4.2.3: Nα-[(9H-Fluoren-9-yl)-methoxycarbonyl]-Nω-
(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-Nω’-(2-
acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranos-1-yl)-L-
arginine (1) 
The allyl ester 5 (200 mg, 0.19 mmol) was dissolved in 
anhydrous THF (10 mL). Pd(PPh3)4 (230 mg, 0.20 mmol) was 
added to the solution followed by phenylsilane (0.25 mL, 2.0 
mmol). The mixture was stirred at 25 °C for 30 min. After the 
reaction was complete (monitored by TLC), the solution was 
concentrated under reduced pressure. The mixture was then 
filtered through a pad of silica with 1% AcOH in ethyl acetate as 
the eluent. The combined filtrate was decolorized over activated 
charcoal, concentrated and purified through reverse-phase HPLC 
to yield the desired -GlcNAcylated arginine building block 1 
(123 mg, 0.13 mmol, 66%) as a white solid following 
lyophilization. [α]D -20 (c 0.19, methanol). IR: 3359 (N-H, O-H), 
1727 (C=O), 1365 (S=O), 1132 (S=O) cm-1. 1H NMR (500 MHz, 
d6-acetone): δ 7.87 (d, 2H, J = 7.5 Hz, Ar-H), 7.74 (d, 2H, J = 7.5 
Hz, Ar-H), 7.42 (tapt, 2H, J = 7.5 Hz, Ar-H), 7.34 (tapt, 2H, J = 7.6 
Hz, Ar-H), 5.40-5.20 (m, 2H, 2 x GlcNAc-H), 5.01, (tapt, 1H, J = 
8.7 Hz, GlcNAc-H), 4.42-4.32 (m, 2H, FmocCH-CH2-O-CO), 
4.27-3.70 (m, 6H, FmocCH-CH2-O-CO, Arg-Hα, 4 x GlcNAc-
H), 3.30-3.20 (m, 2H, Arg-Hδ), 3.00 (s, 2H, Ar-CH2), 2.60 (s, 
3H, Ar-CH3), 2.52 (s, 3H, Ar-CH3), 2.15-1.85 (m, 16H, Ar-CH3 4 
x Ac, Arg-Hβa), 1.85-1.75 (m, 1H, Arg-Hβb), 1.74-1.64 (m, 2H, 
Arg-Hγ), 1.44 (s, 6H, C-(CH3)2) ppm. 13C NMR (125 MHz, d6-
acetone): 173.9, 170.8, 170.1, 159.2, 157.2, 155.3, 145.1, 145.0, 
142.1, 138.9, 135.1, 133.0, 128.5, 128.0, 128.0, 126.2, 125.4, 
120.8, 117.6, 87.1, 82.0, 73.7, 73.5, 69.7, 67.2, 62.8, 54.4, 48.1, 
43.6, 41.7, 29.6, 28.7, 26.5, 22.9, 20.7, 20.64, 20.62, 19.5, 18.3, 
12.5 ppm. HRMS: (+ESI) Calcd. for C48H60N5O15S  [M + H]+ 
m/z, 978.3801, found: 978.3812 
4.2.4: Nα-[(9H-fluoren-9-yl)-methoxycarbonyl]-Nω-(2-
acetoamino-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranos-1-yl)-
L-arginine (6) 
Fmoc-Arg(-GlcNAc,Pbf)-OH 1 (40 mg, 0.04 mmol) was 
suspended in TFA/i-Pr3SiH/H2O (18:1:1, v/v/v, 10 ml) at 25 °C. 
The mixture was stirred vigorously for 60 min before 
concentrating under reduced pressure. The residue was purified 
by RP-HPLC to yield Fmoc-Arg(-GlcNAc)-OH 6 as the 
trifluoroacetate salt (25.0 mg, 0.028 mmol, 71%) as white solid 
after lyophilization. [α]D -14 (c 0.40, methanol). IR: 3360 (N-H), 
3216 (O-H), 1674 (C=O) cm-1. 1H NMR (400 MHz, CD3OD): δ 
7.82 (d, 2H, J = 7.5 Hz, Ar-H), 7.68 (tapt, 2H, J = 7.5 Hz, Ar-H), 
7.42 (tapt, 2H, J = 7.5 Hz, Ar-H), 7.32 (tapt, 2H, J = 7.3 Hz, Ar-H), 
5.28 (tapt, 1H, J2,3 = J3,4 = 9.9 Hz, H-3), 5.06 (tapt, 1H, J3,4 = J4,5 = 
9.7 Hz, H-4), 5.03 (d, 1H, J1,2 = 9.4 Hz, H-1), 4.45-4.37 (m, 2H, 
FmocCH-CH2-O-CO), 4.32 (dd, 1H, J5,6a = 4.0 Hz, J6a,6b = 12.5 
Hz, H-6a), 4.30-4.25 (m, 1H, FmocCH-CH2-O-CO), 4.22-4.16 
(m, 1H, Arg-Hα), 4.15 (dd, 1H, J5,6b = 1.0 Hz, J6a,6b = 12.5 Hz, H-
6b), 4.03 (br, 1H, H-2), 3.96 (ddd, 1H, J4,5 = 10.0 Hz, J5,6a = 4.0 
Hz, J5,6b = 1.0 Hz, H-5), 3.40-3.20 (m, 2H, Arg-Hδ), 2.01-2.00 
(m, 9H, 3 x Ac), 1.96-1.90 (m, 4H, Ac, Arg-Hβa), 1.80-1.60 (m, 
3H, Arg-Hβb and 2 x Arg-Hγ). 13C NMR (100 MHz, CD3OD): 
173.9, 172.9, 170.8, 170.3, 169.8, 157.4, 156.3, 143.9, 143.7, 
141.2, 127.4, 126.8, 124.8, 124.8, 119.5, 72.8, 72.4, 68.1, 66.6, 
61.5, 53.3, 52.9, 40.9, 28.5, 24.8, 21.3, 19.2, 19.1, 19.1 ppm. 
HRMS: (+ESI) Calcd. for C35H44N5O12 [M + H]+ m/z, 726.2981, 
found: 726.2978. 
4.3 General procedures for glycopeptide synthesis 
4.3.1: Preloading of Chemmatrix® Trtyl-OH Resin 
Chemmatrix® Trtyl-OH resin (loading capacity 0.3 mmol/g, 
0.2 g) was swelled in dichloromethane (6 mL) for 30 min. A 
solution of 2% SOCl2 in dichloromethane (6 mL) was then added 
and the resin was shaken for 2 h. After filtration, the resin was 
washed with dichloromethane (5 x 3 mL) and DMF (5 x 3 mL). 
Then a solution of Fmoc-AA-OH (1 mmol) and iPr2NEt (2 
mmol) in dichloromethane (3 mL) was added into the resin and 
the mixture was agitated for 3 h. The resin was again washed 
with DMF (5 x 3 mL), dichloromethane (5 x 3 mL) and DMF (5 
x 3 mL). 
4.3.2: Fmoc deprotection 
The resin was treated with piperidine (20% v/v) in DMF (5 
mL, 2 x 5 min, 25 °C) and then washed with DMF (5 x 3 mL), 
dichloromethane (5 x 3 mL) and DMF (5 x 3 mL). 
4.3.3: Coupling of standard amino acids 
A solution of Fmoc-AA-OH (4 equiv.), N,N’-
diisopropylcarbodiimide (DIC, 4 equiv.), and Oxyma (4 equiv.) 
in DMF (3 mL) was added to the resin and the mixture was 
agitated at 50 °C for 25 min. After filtration, the resin was 
washed with DMF (5 x 3 mL), dichloromethane (5 x 3 mL) and 
DMF (5 x 3 mL). 
4.3.4: Coupling of glycosylated arginine building block 1 
A solution of Fmoc-Arg(-GlcNAc,Pbf)-OH 1 (2.1 equiv.), 
HATU (2.0 equiv.), HOAt (3.0 equiv.) and sym-collidine (2.2 
equiv.) in DMF (3 mL) was added to the resin and the mixture 
was agitated at 25 °C for 18 h. After filtration, the resin was 
washed with DMF (5 x 3 mL), dichloromethane (5 x 3 mL) and 
DMF (5 x 3 mL). 
4.3.5: Capping 
A solution of Ac2O/pyridine (1:9, v/v, 3 mL), was added to 
the resin. The mixture was agitated at 25 °C for 5 min. After 
filtration, the resin was washed with DMF (5 x 3 mL), 
dichloromethane (5 x 3 mL) and DMF (5 x 3 mL). 
4.3.6: Resin cleavage and deprotection 
 After washing thoroughly with dichloromethane (10 x 5 mL), 
the resin was suspended in TFA/i-Pr3SiH/H2O (18:1:1,v/v/v) for 
2 h. After filtration, the filtrate was concentrated by blowing with 
a gentle flow of nitrogen gas. The residue was then re-dissolved 
in MeOH (5 mL). NaOMe (0.5 M in MeOH, 1 mL) was added 
into the solution to give a final pH of 8-9. The resulting solution 
was stirred at 25 °C for 2 h. After completion (reaction 
monitoring by UPLC-MS), the reaction was quenched with 
formic acid (100 μL). The resulting mixture was concentrated 
and purified with RP-HPLC. 
4.4 Synthesis of glycopeptides 7 and 8 
4.4.1: TRADD glycopeptide (7) 
 The synthesis of TRADD peptide fragment peptide 7 was 
conducted on a 25 μmol scale based on a Fmoc-loading assay 
after loading the first amino acid. After HPLC purification and 
lyophilization, the peptide was obtained as a white powder (9.9 
mg, 6.5 μmol, 26%). 1H NMR (400 MHz, CD3OD): δ 4.70 (d, 
1H, JH1,H2 = 9.7 Hz, GlcNAc-H1), 4.50–4.30 (m, 5H, 2 x Arg-Hα, 
Ser-Hα, Leu-Hα, Gln-Hα), 4.25 (d, 1H, Val-Hα), 4.10-3.76 (m 
6H, 2 x Gly-Hα, 2 x Ser-Hβ, GlcNAc-H2, GlcNAc-H6a), 3.72 
(dd, 1H, JH5,H6b = 5.7 Hz, JH6a,H6b = 11.8 Hz, GlcNAc-H6b), 3.57 
(tapt, 1H, JH2,H3 = JH3,H4 = 9.7 Hz, GlcNAc-H3), 3.50-3.40 (m, 1H, 
GlcNAc-H5), 3.37 (tapt, JH3,H4 = JH4,H5 = 9.0 Hz, GlcNAc-H4), 
3.30-3.20 (m, 4H, 4 x Arg-Hδ), 2.98 (t, 2H, 2 x Lys-Hε), 2.37 (t, 
2H, 2 x Gln-Hγ), 2.20-1.40 (m, 23H, Ac, 2 x Lys-Hβ, 2 x Lys-
Hγ, 2 x Lys-Hδ, 4 x Arg-Hβ, 4 x Arg-Hγ, Val-Hβ, 2 x Leu-Hβ, 
Leu-Hγ, 2 x Gln-Hβ), 1.03 (d, 6H, J = 6.2 Hz, 6 x Val-Hγ), 0.98 
(d, 3H, J = 6.2 Hz, 3 x Leu-Hδ), 0.94 (d, 3H, J = 6.1 Hz, 3 x Leu-
Hδ). HRMS: (+ESI) Calcd. for C47H88N17O16  [M + H]+ m/z 
1146.6587, Found: 1146.6600. LRMS: (MALDI-TOF) m/z, [M 
+ H]+, Calcd: 1146.66, Found: 1146.67. 
 
4.4.2 FADD glycopeptide 8 
The synthesis of FADD peptide fragment peptide 14 was 
conducted on a 25 μmol scale based on a Fmoc-loading assay 
after loading the first amino acid. After HPLC purification and 
lyophilization, the peptide was obtained as a white powder (13.9 
mg, 7.5 μmol, 30%). 1H NMR (400 MHz, CD3OD): δ 4.67 (d, 
1H, JH1,H2 = 9.7 Hz, GlcNAc-H1), 4.50–4.20 (m, 9H, Arg-Hα, 
Ser-Hα, 2 x Leu-Hα, 2 x Glu-Hα, 2 x Ala-Hα, Lys6-Hα), 4.11 (d, 
1H, Val-Hα), 3.95-3.85 (m, 3H, Ser-Hβa, Lys11- Hα, GlcNAc-
H6a), 3.85-3.75 (m, 2H, Ser-Hβa, GlcNAc-H2), 3.70 (dd, 1H, 
JH5,H6b = 5.8 Hz, JH6a,H6b = 11.9 Hz, GlcNAc-H6b), 3.54 (tapt, 1H, 
JH2,H3 = JH3,H4 = 9.5 Hz, GlcNAc-H3), 3.50-3.40 (m, 1H, 
GlcNAc-H5), 3.34 (tapt, JH3,H4 = JH4,H5 = 9.1 Hz, GlcNAc-H4), 
3.25-3.15 (m, 2H, 2 x Arg-Hδ), 3.00-2.90 (m, 4H, 4 x Lys-Hε), 
2.50-2.40 (m, 4H, 4 x Glu-Hγ), 2.22-1.34 (m, 36H, Ac, 4 x Lys-
Hβ, 4 x Lys-Hγ, 4 x Lys-Hδ, 2 x Arg-Hβ, 2 x Arg-Hγ, Val-Hβ, 4 
x Leu-Hβ, 2 x Leu-Hγ, 4 x Glu-Hβ, 6 x Ala-Hβ), 1.10-0.80 (m, 
18H, 6 x Val-Hγ, 12 x Leu-Hδ. HRMS: (+ESI) Calcd. for 
C62H113N17O22  [M + 2H]2+ m/z, 723.9118, Found: 723.9118. 
LRMS: (MALDI-TOF) m/z, [M + H]+, Calcd: 1446.81, Found: 
1446.79. 
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